Drugs / GSK5460025
last change Oct 2025 re-read 3 minutes ago

GSK5460025

Developed for
colorectal neoplasm
Investigated by
GlaxoSmithKline

Trials 1

202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT07213609 Oct 2025 → Sep 2028 expected colorectal neoplasm GlaxoSmithKline Recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as GSK5460025 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07213609 ↗